Intellect Neurosciences Inc. (fka ILNS)

[itwillgetbetter]

I disagree just read what Chain the prior CEO/scientist stated when the Notice of Allowance was issued and patent issued there after.

I'm no scientist but to me PF-04360365 imo is covered under the license and patent which in no way has expired it was just issued in the summer of 2012.They are so closely related is my thought A/D,Probable Cerebral Amyloid Angiopathy.Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aß40.

My point is to I believe it was field 1.9 the licensee agreement the defense filed in the prior ligation which was settled stated other diseases so imo it's covered and hopefully other claims will be issued also that were pending.

Really Chain would know in 5 seconds and since he is not there anymore its speculating trying to understanding something I'm clueless cause I'm no scientist and if you see me in the operating room before you go to sleep get the hell out of there cause I'm no surgeon either!

This is where we need company communication with its shareholders and the public at large however I remember Elliot telling me PONEZUMAB was covered may have misunderstood but don't think so.



http://www.prnewswire.com/news-releases/intellect-neurosciences-receives-notice-of-allowance-from-united-states-patent-and-trademark-office-for-its-antisenilin-alzheimers-disease-immunotherapy-technology-platform-141561013.html



The best-known example of a therapeutic antibody that binds to the free C-terminus of beta amyloid 1-40 is ponezumab (aka PF-04360365). A phase 1 study to determine effect of PF-04360365 on clearance of beta amyloid from cerebrospinal fluid in patients with Alzheimer's disease and healthy volunteers is currently recruiting patients according to www.ClinicalTrials.gov and verified by Pfizer in February 2012. This trial, which is scheduled to complete in August 2012, follows other completed Phase 1 and 2 trials.